Search results
Paxlovid Doesn't Cure Long COVID
Time via Yahoo News· 3 days agoThe rest of the group took a placebo with ritonavir, which doesn't work against the SARS-CoV-2 virus on its own. Ritonavir enhanced the placebo because...
The Power of Placebo To Boost High Performance and Self-Belief
Sean Kernan via Yahoo News· 5 days ago“Want another beer Brian?” My buddy Adam said. “Sure! I’ve already had three, but why not,” Brian...
Michael Mosley, exuberant medical broadcaster who popularised the 5:2 diet – obituary
The Telegraph via Yahoo News· 23 hours agoDr Michael Mosley, who has died in Greece aged 67, was a Tiggerish presenter of television science...
A call to ban phones in school
Politico· 6 days agoWhy it matters: There...National Institute on Drug Abuse, Nora Volkow, compared the hype for psychedelics as a cure for mental illness to belief in...
'Outstanding' Results for Osimertinib: Stage III EGFR+ NSCLC
Medscape· 6 days agoResults from the LAURA trial will change practice once its label gets expanded, experts said at the...
The psychedelic medicine revolution just took a big loss
Politico via Yahoo News· 6 days agoIn its 2023 trial, Lykos said 71 percent of participants who received the combo treatment no longer met the criteria for PTSD...National Institute on Drug Abuse, Nora Volkow, last month compared ...
Harrods, Las Vegas and here: Region part of vitamin IV trend
The Times-Tribune, Scranton, Pa. via Yahoo News· 6 days agoIt is a Kardashian favorite and a longstanding trend that you can join right here. IV vitamin drips at wellness businesses are enjoyed by many celebrities and dismissed by many doctors. At least ...
Brii Bio Presents New Data from Its Ongoing Phase 2 Chronic Hepatitis B Trials at EASL™ Congress...
The Tomahawk· 3 days agoNew translational data demonstrate that BRII-179-induced immune responses are associated with high HBsAg reduction in a subset of participants with chronic HBV infection
Gilead’s Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in...
Morningstar· 5 days agoGilead Sciences, Inc. (Nasdaq: GILD), following the recent acquisition of CymaBay Therapeutics, Inc., today announced two-year interim results from the ongoing ASSURE study of investigational ...